184 related articles for article (PubMed ID: 36454568)
1. Evaluation of Concurrent Chemoradiotherapy for Survival Outcomes in Patients With Synchronous Oligometastatic Esophageal Squamous Cell Carcinoma.
Shi Z; Zhu X; Ruan C; Wei G; Li J; Qiu H; Gao L; Cai G; Zhangcai Y; Li B; Wang J; Gong Y; Chen J; Zhao W; Wu Y; Ke S; Chen Y
JAMA Netw Open; 2022 Dec; 5(12):e2244619. PubMed ID: 36454568
[TBL] [Abstract][Full Text] [Related]
2. Survival impact of concurrent chemoradiotherapy for elderly patients with synchronous oligometastatic esophageal squamous cell carcinoma: A propensity score matching and landmark analyses.
Shi Z; Zhu X; Ke S; Qiu H; Cai G; Zhangcai Y; Chen Y
Radiother Oncol; 2021 Nov; 164():236-244. PubMed ID: 34627936
[TBL] [Abstract][Full Text] [Related]
3. Short-term response might influence the treatment-related benefit of adjuvant chemotherapy after concurrent chemoradiotherapy for esophageal squamous cell carcinoma patients.
Liu A; Wang Y; Wang X; Zhu L; Nie Y; Li M
Radiat Oncol; 2021 Oct; 16(1):195. PubMed ID: 34600574
[TBL] [Abstract][Full Text] [Related]
4. Induction immunotherapy plus chemotherapy followed by definitive chemoradiation therapy in locally advanced esophageal squamous cell carcinoma: a propensity-score matched study.
Lian HM; Wu JL; Liufu WJ; Yu TT; Niu SQ; Bao Y; Peng F
Cancer Immunol Immunother; 2024 Feb; 73(3):55. PubMed ID: 38366287
[TBL] [Abstract][Full Text] [Related]
5. Feasibility and efficiency of concurrent chemoradiotherapy with a single agent or double agents vs radiotherapy alone for elderly patients with esophageal squamous cell carcinoma: Experience of two centers.
Huang C; Zhu Y; Li Q; Zhang W; Liu H; Zhang W; Hu Y; Yuan Y; Liu M
Cancer Med; 2019 Jan; 8(1):28-39. PubMed ID: 30600600
[TBL] [Abstract][Full Text] [Related]
6. With or without consolidation chemotherapy using cisplatin/5-FU after concurrent chemoradiotherapy in stage II-III squamous cell carcinoma of the esophagus: A propensity score-matched analysis.
Chen Y; Guo L; Cheng X; Wang J; Zhang Y; Wang Y; Ke S; Shi W
Radiother Oncol; 2018 Oct; 129(1):154-160. PubMed ID: 29122362
[TBL] [Abstract][Full Text] [Related]
7. Concurrent chemoradiotherapy versus radiotherapy alone for patients with locally advanced esophageal squamous cell carcinoma in the era of intensity modulated radiotherapy: a propensity score-matched analysis.
Li C; Tan L; Liu X; Wang X; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Wang X; Bi N; Deng L; Wang W; Zhang T; Ni W; Chang X; Han W; Gao L; Wang S; Xiao Z
Thorac Cancer; 2021 Jun; 12(12):1831-1840. PubMed ID: 33949784
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for stage IV esophageal squamous cell carcinoma: a retrospective controlled study.
Lyu J; Li T; Wang Q; Li F; Diao P; Liu L; Li C; Lang J
Radiat Oncol; 2018 Nov; 13(1):233. PubMed ID: 30477531
[TBL] [Abstract][Full Text] [Related]
9. Sintilimab as maintenance treatment for local/regional recurrent esophageal squamous carcinoma after concurrent chemoradiotherapy: a single-arm Ib/II phase study.
Liu C; Sun H; Huang W; Wang Z; Fu C; Han D; Zhao Q; Wu X; Li B
Front Immunol; 2023; 14():1193394. PubMed ID: 37325650
[TBL] [Abstract][Full Text] [Related]
10. The Safety and Efficacy of Apatinib Treatment in Addition to Concurrent Chemoradiotherapy in Patients with Nonoperative Locally Advanced Esophageal Squamous Cell Carcinoma.
Hu L; Kong Z; Meng Q; Wang J; Zhou M; Yu J; Jiang X
Med Sci Monit; 2020 Nov; 26():e927221. PubMed ID: 33243967
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitors combined with concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.
Huang JQ; Liang HW; Liu Y; Chen L; Pei S; Yu BB; Pan XB
Front Immunol; 2024; 15():1355198. PubMed ID: 38550598
[TBL] [Abstract][Full Text] [Related]
12. Clinical Effect of Radiotherapy Combined with Chemotherapy for Non-Surgical Treatment of the Esophageal Squamous Cell Carcinoma.
Chen H; Zhou L; Yang Y; Yang L; Chen L
Med Sci Monit; 2018 Jun; 24():4183-4191. PubMed ID: 29915168
[TBL] [Abstract][Full Text] [Related]
13. Survival comparision of three-dimensional radiotherapy alone with concurrent chemoradiotherapy for non-surgical esophageal carcinoma.
Tan L; Xiao Z; Zhang H; Chen D; Feng Q; Zhou Z; Lv J; Liang J; Yin W
Cancer Radiother; 2020 Feb; 24(1):21-27. PubMed ID: 32001131
[TBL] [Abstract][Full Text] [Related]
14. Concurrent chemoradiotherapy combined with enteral nutrition support: a radical treatment strategy for esophageal squamous cell carcinoma patients with malignant fistulae.
Ma L; Luo GY; Ren YF; Qiu B; Yang H; Xie CX; Liu SR; Liu SL; Chen ZL; Li Q; Fu JH; Liu MZ; Hu YH; Ye WF; Liu H
Chin J Cancer; 2017 Jan; 36(1):8. PubMed ID: 28077159
[TBL] [Abstract][Full Text] [Related]
15. Comparative study of radiotherapy plus erlotinib versus chemoradiotherapy for elderly patients with esophageal cancer: a propensity score-matched analysis.
Song T; Du D; Zhang X; Fang M; Wu S
Dis Esophagus; 2017 Sep; 30(9):1-10. PubMed ID: 28859362
[TBL] [Abstract][Full Text] [Related]
16. Benefit of chemotherapy based on platinum with definitive radiotherapy in older patients with locally advanced esophageal squamous cell carcinoma.
Wu H; Yu Y; Zheng Q; Liu T; Wu Y; Wang Z; Zheng H; Liu L; Li J
Radiat Oncol; 2021 Oct; 16(1):207. PubMed ID: 34717670
[TBL] [Abstract][Full Text] [Related]
17. Definite intensity-modulated radiotherapy with concurrent chemotherapy more than 4 cycles improved survival for patients with locally-advanced or inoperable esophageal squamous cell carcinoma.
Hsieh HY; Hsu CP; Yeh HL; Chuang CY; Lin JF; Chang CF
Kaohsiung J Med Sci; 2018 May; 34(5):281-289. PubMed ID: 29699635
[TBL] [Abstract][Full Text] [Related]
18. Elective nodal irradiation versus involved-field irradiation for stage II-IV cervical esophageal squamous cell carcinoma patients undergoing definitive concurrent chemoradiotherapy: a retrospective propensity study with 8-year survival outcomes.
Wang J; Wu Y; Zhang W; Chen Y; Liu Q; Jing S; Zhang J; Wu F; Wang J; Qiao X
Radiat Oncol; 2023 Aug; 18(1):142. PubMed ID: 37641149
[TBL] [Abstract][Full Text] [Related]
19. Age plays an important role in the decision of definitive concurrent chemoradiotherapy (CCRT) for esophageal squamous cell carcinoma (ESCC): a propensity-score matched analysis of multicenter data (3JECROG R-02A).
Wang L; Wang X; Ren X; Han C; Xiao Z; Zhu S; Qiao X; Zhou Z; Shen W; Chen J; Pang Q; Zhang W; Zhao Y; Wang X; Sun X; Ge X; Zhang K; Hu M; Li G; Liu M; Wang Y
Transl Cancer Res; 2021 Jun; 10(6):2932-2943. PubMed ID: 35116602
[TBL] [Abstract][Full Text] [Related]
20. Value and application of trimodality therapy or definitive concurrent chemoradiotherapy in thoracic esophageal squamous cell carcinoma.
Lin WC; Ding YF; Hsu HL; Chang JH; Yuan KS; Wu ATH; Chow JM; Chang CL; Chen SU; Wu SY
Cancer; 2017 Oct; 123(20):3904-3915. PubMed ID: 28608916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
